Antithrombotics: In A Crowded Field Of Candidates, Does Being First Matter?
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
The cresting wave of novel antithrombotic NDAs could mean 2010 will be a difficult year for FDA's Division of Cardiovascular and Renal Products, as the products have massive applications and tricky risk-benefit evaluations.